[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642229":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":36,"responsibleParty":107,"collaborators":109,"id":116,"slug":117,"hasResults":118,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":118,"sex":124,"minAge":125,"maxAge":20,"enrollmentInfo":126,"targetDuration":20,"studyType":129,"phases":130,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":73,"whyStopped":20,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":149},{"fullName":5,"class":6},"Allterum Therapeutics, Inc","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Arm","EXPERIMENTAL","Participants receive 4A10 administered by intravenous route according to the protocol-defined dosing schedule in 28-day cycles until disease progression, unacceptable toxicity, withdrawal of consent, or discontinuation per investigator decision.",[13],"Drug: 4A10",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","4A10","4A10 (Molecule B4532) is an investigational human Immunoglobulin G Subclass 1 (IgG1) monoclonal antibody that specifically binds CD127 (Interleukin-7 receptor alpha subunit, IL-7Rα). CD127 is a component of the interleukin-7 receptor and the thymic stromal lymphopoietin receptor (TSLPR), which are expressed on T-cell acute lymphoblastic leukemia (T-ALL) and pre-B-cell acute lymphoblastic leukemia (B-ALL) cells.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Eric Schafer, MD","Baylor College of Medicine","STUDY_CHAIR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Shibani M Kudchadkar, MD","CONTACT","15153439875","skudchadkar@allterum.com",{"name":33,"role":29,"phone":34,"phoneExt":20,"email":35},"Yan Moore, MD, MBA","6178004959","ymoore@allterum.com",[37,56,71,94],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Children's Hospital Colorado","NOT_YET_RECRUITING","Aurora","Colorado","80045","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-104.83192,39.72943,{"lat":49,"lon":48},[52],{"name":53,"role":29,"phone":54,"phoneExt":20,"email":55},"Kelly Faulk, MD","(720)777-6740","Kelly.Faulk@childrenscolorado.org",{"facility":57,"status":39,"city":58,"state":59,"zip":60,"country":43,"countryCode":44,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Children's Hospital of Philadelphia","Philadelphia","Pennsylvania","19104",{"type":46,"coordinates":62},[63,64],-75.16362,39.95238,{"lat":64,"lon":63},[67],{"name":68,"role":29,"phone":69,"phoneExt":20,"email":70},"Susan Rheingold, MD","(267) 426-0762","rheingold@chop.edu",{"facility":72,"status":73,"city":74,"state":75,"zip":76,"country":43,"countryCode":44,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Cook Children's Medical Center","RECRUITING","Fort Worth","Texas","76104",{"type":46,"coordinates":78},[79,80],-97.32085,32.72541,{"lat":80,"lon":79},[83,87,91],{"name":84,"role":29,"phone":85,"phoneExt":20,"email":86},"Heather Jernigan","682-885-2103","Heather.Jernigan@cookchildrens.org",{"name":88,"role":29,"phone":89,"phoneExt":20,"email":90},"Andrea Martinez","682-303-3061","andrea.martinez@cookchildrens.org",{"name":92,"role":93,"phone":20,"phoneExt":20,"email":20},"Holly Pacenta, MD","PRINCIPAL_INVESTIGATOR",{"facility":95,"status":39,"city":96,"state":75,"zip":97,"country":43,"countryCode":44,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Texas Children's Hospital","Houston","77030",{"type":46,"coordinates":99},[100,101],-95.36327,29.76328,{"lat":101,"lon":100},[104],{"name":23,"role":29,"phone":105,"phoneExt":20,"email":106},"(832) 822-3300","esschafe@texaschildrens.org",{"type":108,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[110,113],{"name":111,"class":112},"National Cancer Institute (NCI)","NIH",{"name":114,"class":115},"Cancer Prevention Research Institute of Texas","OTHER","100642229","phase-1-first-in-human-study-of-a-new-treatment-4a10-for-patients-with-relapsed-or-hard-to-treat-acute-lymphoblastic-leukemia-or-lymphoblastic-lymphoma-focused-on-safety-and-how-the-drug-behaves-in-the-body-and-early-signs-of-effect-100642229",false,"NCT07586618","First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.","A First in Human, Phase 1, Open-Label Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 4A10 Monotherapy In Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","ALT-101","Key Inclusion Criteria:\n\n1. Confirmed diagnosis of T\u002FB-ALL or T\u002FB-LL\n2. Relapsed or refractory disease without curative options\n3. Adequate organ function and performance status\n\nKey Exclusion Criteria:\n\n1. Patients with CNS3 disease\n2. Patients with DNA fragility syndromes (e.g., Fanconi, Bloom), trisomy 21 (Down Syndrome)\n3. Prior exposure to anti-CD127 therapies\n4. Uncontrolled infections","ALL","18 Years",{"count":127,"type":128},24,"ESTIMATED","INTERVENTIONAL",[131],"PHASE1","ALT-101 is a first-in-human Phase 1 clinical trial testing a new antibody drug called 4A10 in patients with relapsed or hard-to-treat acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma.\n\n4A10 is a targeted therapy designed to recognize and attach to a specific protein (CD127) found on leukemia cells. Once it binds, it works in two ways: it blocks growth signals that help cancer cells survive, and it helps the immune system find and destroy those cancer cells.\n\nIn this study, patients receive 4A10 through an intravenous (IV) infusion once a week. The main goal of the trial is to find out if the drug is safe, what dose can be given, and how the body processes it. Researchers will also look for early signs that the treatment may be working.\n\nThe study starts with small groups of patients receiving increasing doses to carefully monitor safety. Each patient is closely observed during the first treatment cycle (about 4-6 weeks) to watch for side effects. If the treatment is helping and is well tolerated, patients may continue treatment for up to six cycles.\n\nOverall, this study is an early step in testing a new, targeted immune-based therapy for difficult-to-treat blood cancers.",[134,135],"Lymphoblastic Lymphoma","Acute Lymphoblastic Leukemia ALL",[137,138,139],"Leukemia","Refractory","Relapsed","2026-06-09",{"date":142,"type":143},"2026-06-11","ACTUAL",{"date":145,"type":143},"2026-06-01",{"date":147,"type":128},"2028-09",{"name":5,"class":6},4]